In Q2 2024, PMDS' US operations contributed 19.8% to the group’s Annual Recurring Revenue (ARR). With this new contract, the company expects its US business to generate sufficient ARR from existing clinics to achieve profitability from year-end onwards—marking a pivotal moment in PMDS’ financial strategy.

“This contract is another critical milestone in our US expansion journey, and it positions us to hit key profitability goals starting from the end of this year,” said Myles Murray, Founder and CEO of PMDS. “We have demonstrated the strength of our business model, and this new partnership builds on that momentum. Our ability to generate sufficient ARR to achieve profitability from year-end onwards underscores the successful execution of our strategy. As more clinics join our network, we are well-positioned to scale rapidly while delivering long-term value to our partners.”

PMDS partners with clinics across the US to provide essential daily monitoring services for patients with chronic health conditions. Acting as an extension of these clinics, PMDS improves patient outcomes by ensuring remote monitoring and care coordination. Medicare, the largest health insurer in the US, reimburses clinics for these services, and the number of Medicare patients served at each clinic is a key indicator of a clinic’s potential. As PMDS continues to onboard new clinics, patient numbers—and revenue—will rise, enabling the company to grow as providers refer patients to our service. The larger the patient base, the greater the ARR potential, with the number of providers accelerating the company’s scalability.

This continued expansion reinforces PMDS' strategy to meet profitability targets and secure its position as a leader in the digital healthcare market, driving sustainable returns for its investors.